{"editorial":{"content_id":"42b78b4c-e7b1-4c5f-9a13-1cac9bb0f7ef","slug":"anvisa-gazyva-repatha-20261105-1c23e2","content_type":"news","title":"巴西Anvisa批准Gazyva与Repatha两项新适应症","summary":"巴西国家卫生监督局批准Gazyva用于成人原发性膜性肾病、Repatha用于高心血管风险人群降低LDL-C两项新适应症。","body":"巴西国家卫生监督局（Anvisa）批准了Gazyva（obinutuzumabe）的新治疗适应症，可用于治疗成人原发性膜性肾病（NMp）；同时批准Repatha（evolocumabe）用于已确诊动脉粥样硬化性心血管疾病或高风险成人，通过降低LDL-C水平降低心血管风险。\n\n据Anvisa说明，Gazyva是一种抗CD20人源化单克隆抗体，可减少B淋巴细胞，从而降低与原发性膜性肾病相关的免疫活性。该病为罕见自身免疫病，特征为蛋白尿、肾病综合征，并有进展为慢性肾病和肾衰竭的风险。Anvisa指出，获得疾病缓解、尤其是完全缓解，与保护肾功能和改善长期预后相关。该适应症申请被纳入RDC 1.001/2025规定的优先标准。\n\nRepatha是一种人IgG2单克隆抗体，通过阻断PCSK9蛋白并增加肝脏LDL受体再循环，显著降低循环LDL-C水平。Anvisa称，LDL-C是动脉粥样硬化性心血管疾病发展的重要致病因素。该病涵盖冠状动脉疾病、动脉粥样硬化性脑血管病和外周动脉疾病，是全球心血管疾病发病和死亡的主要原因之一；尽管他汀类、依折麦布及非药物措施广泛使用，许多患者LDL-C水平仍偏高，残余心血管风险显著。\n\nAnvisa表示，Repatha新适应症主要依据一项在33个国家745个中心开展的研究结果：共随访12257名心血管高风险、无心肌梗死或卒中既往史的患者，平均随访55个月。相关决议为《联邦官方公报》上的第4.249/2026号决议。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-11-05T23:01:43.584Z","display_date":"2026-11-05","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-novo-tratamento-para-nefropatia-membranosa-primaria","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-gazyva-repatha-20261105-1c23e2","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-gazyva-repatha-20261105-1c23e2","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-gazyva-repatha-20261105-1c23e2?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-gazyva-repatha-20261105-1c23e2?view=json","last_updated":"2026-11-05T23:02:08.196Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}